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Successful adoption of POCTs (Point-of-Care tests) for COVID-19 in care homes requires the 
identification of ideal use cases and a full understanding of contextual and usability factors that affect 
test results and minimise biosafety risks. This paper presents findings from a scoping-usability and 
test performance study of a microfluidic immunofluorescence assay for COVID-19 in care homes.  
Methods 
A mixed-methods evaluation was conducted in four UK care homes to scope usability and to assess 
the agreement with qRT-PCR. A dry run with luminescent dye was carried out to explore biosafety 
issues.   
Results 
The agreement analysis was carried out on 227 asymptomatic participants (159 staff and 68 residents) 
and 14 symptomatic participants (5 staff and 9 residents). Asymptomatic specimens showed 50% 
(95% CI: 1.3%-98.7%) positive agreement and 96% (95% CI: 92.5%-98.1%) negative agreement with 
overall prevalence and bias-adjusted Kappa (PABAK) of 0.911 (95% CI: 0.857-0.965). Symptomatic 
specimens showed 83.3% (95% CI: 35.9%-99.6%) positive agreement and 100% (95% CI: 63.1%-
100%) negative agreement with overall prevalence and bias-adjusted Kappa (PABAK) of 0.857 (95% 
CI: 0.549-1).  
The dry run showed four main sources of contamination that led to the modification of the standard 
operating procedures. Simulation after modification showed no further evidence of contamination. 
Conclusion  
Careful consideration of biosafety issues and contextual factors associated with care home are 
mandatory for safe use the POCT.  Whilst POCT may have some utility for ruling out COVID-19, 
further diagnostic accuracy evaluations are needed to promote effective adoption.  
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Background 
Protecting care homes from COVID-19  is complex[1] [2] [3] and will continue to be challenged by 
immunosenescence in care home populations [4] and the emergence of new strains [5], even after the 
widespread roll-out of vaccines.  Minimising ingress into homes [6] can help reduce the risk of 
infection but restricting visiting can cause physical and mental deconditioning in residents and may 
contravene fundamental human rights [7].   
Testing regimes may help facilitate safe opening of care homes by enabling early identification of 
infection through rapid establishment of COVID-19 status for those who are symptomatic, and 
through regular screening of those who are asymptomatic. Laboratory based reverse-transcriptase 
polymerase chain reaction (RT-PCR) tests are considered to be highly sensitive and specific but 
results may take more than 24 hours to be received, and sometimes several days to return to care 
homes, making them suboptimal for outbreak management [8]. Widely deployed lateral flow device 
(LFD) antigen tests provide results within 30 minutes but normally have lower sensitivity and 
specificity than RT-PCR  and present other use challenges in a care home context  [9, 10]. Changes in 
sensitivity of LFDs have been reported as a direct consequence of the context of use and when carried 
out by untrained healthcare workers [11, 12]. These findings demonstrate that successful adoption of a 
diagnostic test requires a fuller understanding of all the factors that affect test results, including user 
competence assessment, risk assessment of testing kits and the environment in which they will be 
used, ease-of-use issues and the prevention of errors. We have previously described the care home 
workstream of the COVID-19 National Diagnostic Research and Evaluation Platform in Care Homes 
(CONDOR-CH), which is a service evaluation project to evaluate novel point of care testing 
technologies for COVID-19 designed to overcome shortcomings of currently used technologies [13].  
The study reported here considers the use in care homes of a microfluidic immunofluorescence assay 
for the direct and qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 (hereafter 
referred as LumiraDx). The COVID-19 testing strip for LumiraDx is designed to be used with 
samples collected from the anterior nares or nasopharyngeal site using a swab eluted into a vial of 
extraction buffer. A single drop of the specimen in extraction buffer is added to the test strip from a 
vial dropper cap. LumiraDx enacts the test protocol using dried reagents within the test strip. The 
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result is determined from the amount of fluorescence detected within the measurement zone of the test 
strip. Analyte concentration in the specimen is proportional to the fluorescence detected. Results are 
displayed on the instrument’s touchscreen within 12 minutes of sample administration.  Test strips are 
single use and disposed of post-assay. The system has been trialled and then subsequently deployed in 
different hospitals across England to inform decision making upon hospital admission.  
This study aimed to:  
• To evaluate diagnostic agreement, usability and biosafety risks of an automated antigen test.  




We conducted a mixed-methods (quantitative/qualitative) [14] evaluation with an agreement study of 
LumiraDx with qRT-PCR in care homes combined with a qualitative explorations of risks in use and 
to mitigate biosafety issues using unmoderated remote usability observation.   
Homes were recruited using a national care home WhatsApp COVID-19 peer support group [15], 
public-facing social media and two national care home organisations: Care England and the National 
Care Forum. It includes nursing and residential homes; corporate chain, independent and third-sector 
providers; with between 20-350 residents per home. From this sampling frame we purposively 
selected four care homes (Appendix I, Table A1): we selected two homes with nursing and two 
without nursing (also known as nursing and residential homes respectively), The homes selected were 
in two regions of the UK, including two independent care homes and two from small chains of 
ownership. The sample was designed to maximise potential differences in staff training, and 
organisational configuration that might impact on implementation of a point-of-care test.  The homes 
selected had previously been involved with the  evaluation of a point-of-care Polymerase Chain 
Reaction (POC-PCR) test [13]. Their experience of deploying other POCTs was felt to provide useful 
contextual information for understanding LumiraDx use. 
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A range of participants were chosen to understand workflows around staff and resident routine testing. 
This sample enabled us to identify possible errors arising from repeated use of the machine, by 
different staff members, on different days, under different circumstances. 
 
Biosafety Issues: There are some challenges associated with deploying LumiraDx in care homes, 
which were important to understand and mitigate against:  
1. Swabbing and eluting specimens into buffer is undertaken in bedrooms that are remote from the 
LumiraDx testing equipment raising potential biosafety issues (e.g.: from handling COVID-19 
positive samples at the bedside, during transfer of the specimen, or upon arrival at the machine) 
due to risks of sample spillage of a potentially infected specimen. 
2. As opposed to standard sample collection techniques for qRT-PCR tests, the swab must be 
swirled, squeezed and removed from the buffer, and then correctly disposed of in a biohazard bin. 
This procedure may expose staff and residents to risks (Fig. 1).  
3. The extracted sample is applied onto the test strip by gently pressing the sides of the extraction 
vial until one whole drop is visible and this procedure may cause contamination of the device and 
testing area (Fig. 2). 
 
  
Fig.1 The operator removes the pa tient swab 
while squeezing the middle of the extraction 
vial to remove the liquid from the swab.  The 
swab  is discarded in biohazard  waste.  
Fig.  2 The operator applies the extracted 
sample from the extraction vial onto the sample 
application area of the inserted test strip.   
 
Simulation to evaluate biosafety issues:  Four care homes took part in a trial with LumiraDx with no 
“live” nasal specimen. Each care homes allocated at least two participants for each site. Where 
applicable, participants were recruited to have mixed background and experience (i.e. staff involved 
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in previous trials with point-of-care tests for SARS-CoV-2 and staff with no prior experience with 
point-of-care tests). A total of nine participants conducted the simulation test 5 times, independently, 
over one week. Staff were asked to follow a standardised operating procedure (SOP) prepared by 
laboratory staff taking account of perceived risks for eluting a swab, transferring the buffer solution, 
and running the LumiraDx test (see SOP; Appendix II).   
Two randomly selected care homes (hereafter called care home A and care home B) were asked to 
conduct the simulation with GloGermTM liquid, a mineral oil-based solution containing proprietary 
powder which fluoresces under ultraviolet light, which was used in place of buffer whilst following 
the SOP.  After replacing LumiraDx buffer with GloGerm, we then asked them to examine their work 
and care areas under an ultraviolet light for signs of spillage or contamination. Verbalisation and 
interactions with the device were video recorded. Pictures of the testing area and device were taken at 
the end of each test. Following this, amendments were made to the SOP (Appendix III) and 10 further 
simulations [one volunteer in each care home (A and B) conducting five tests] were run to assess 
whether this had rectified the identified risks.  
 
Usability and use errors: Usability, potential sources of error, and ways of mitigating the risk 
(updated SOP) during routine test use with “live” specimens were the focus of semi-structured 
interviews with key stakeholders from four care homes. All interviews were undertaken remotely by a 
researcher in human factors (MM) at the conclusion of the trial. Interviews were semi-structured, 
lasted between 30 and 60 minutes, and were audio and video recorded with the interviewees’ 
permission. Interview schedules focused on manufacturer instructions for use, how LumiraDx might 
be integrated into the diagnostic pathway, the testing strategy and clinical decision making arising 
from positive and negative results. Interviewees from the four care homes were then prompted to 
explore potential usability issues such as clarity of test results, potential hazards and disposal 
procedures. Interviewees took part on a voluntary basis and did not receive compensation for their 
time.  
Qualitative data were thematically analysed [16, 17]. Coding of the responses were performed by one 
researcher (MM) and codes were agreed following expert review with other human factors experts 
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within the research  team. Interviewees consented  prior to the study and video interviews were 
recorded using conferencing platforms (MS Teams, Zoom.) Recordings were transcribed using AI 
transcription software (Otter.ai).  Recording, transcription files and video materials were stored on a 
password-protected secure server. Enrolled participants were assigned a confidential identification 
number (IC) on consent, to be used on all corresponding data.  
 
Diagnostic agreement: The test was evaluated using specimens taken from both staff and residents as  
asymptomatic transmission from staff is an important factor in care home outbreaks [18]. We focused 
on routine staff testing; currently conducted three times per week, twice with lateral flow tests and 
once with send-off qRT-PCR. This high frequency, mixed regimen testing, generates significant 
workload for care home staff and makes that work more complicated [19]. We estimated that 
conducting 60 tests in each of the four care homes would allow enough repetition of the testing 
procedure to capture variability in practice between people and over time. We sought to conduct: 35 
routine staff tests; 15 routine resident tests; and 10 tests for resident or staff who developed 
symptoms. Anterior nares swabs were taken by care home staff using the aforementioned SOP and 
adhering to standard testing procedures and kits recommended by the manufacturer (see Appendix II). 
All swab tests were taken by a member of the care home staff team. Staff did not self-swab. A paired 
nasopharyngeal swab for laboratory analysis was taken immediately after the LumiraDx swab using 
recommended UK Governmental guidance.  Care home staff recorded LumiraDx test results using a 
results log, adding formal laboratory results when they became available. Unblinded but anonymised 
data were available to the research team. For the purpose of this study, LumiraDx was used in a 
dedicated testing area, fixed to a benchtop.  Only formally trained staff members were permitted to 
use the machine.  
No formal power calculation was undertaken. LumiraDx, in non-care home settings, has a reported  
sensitivity of 83.8% (95% CI: 76.4-89.2%) and specificity of 98.7% (95% CI 97.2-99.4%) with RT-
PCR [20] as the reference method.  Our objective was evaluating agreement between LumiraDx and 
qRT-PCR when the test was deployed in care home settings. All test results, including equivocal 
results and failures, were reported as per US Food and Drug Administration (FDA) guidance [21]. We 
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calculated positive and negative agreement of LumiraDx with qRT-PCR results, (Cohen) Kappa, and 
the Brennan and Prediger statistic (equal to the prevalence and biased adjusted kappa (PABAK)) with 
associated 95% confidence intervals. Primary analysis was based on valid results for all tests stratified 
by symptomatic/asymptomatic participants. Calculations were carried out in Stata/SE 16.1 Sensitivity 
analysis to examine the impact of equivocal results and test failures was undertaken.  
 
Results 
Biosafety Simulations  
Four main sources of contamination with GloGerm dye (Table 2) occurred. Table 2 shows UV LED 
images of operators after conducting the test with the GloGerm and mitigation strategies.  These data 
along with interviews, led to the modification of the SOP (Appendix III) to improve glove, 
contaminated material and specimen handling at the bedside and the cleaning of surfaces after use. 
Simulation after modification showed no further evidence of contamination (Table 3).  
 
Table 1 - Biosafety issues identified using GloGerm dye during the simulation  
 Care home A 
 
Care home B 





Description Sta ins on PPE  
(gloves)  
Splash marks  on the  
benchtop 
Marks on th e waste  
b in  
S tain s on PPE 
(g loves  –  top han d)  
Possible 
reasons 
Liqu id spil t  when 
screwin g o n the 
buf fer  l id; Liquid  
spi lt  when handl ing  
co ntaminated 
materia l (buf fer ,  
Liquid  sp il t  when 
pul ling  swab out. 
Liquid  sp il t  when 
ti lt ing  the  buf fer 
container 
Accid en tal samp le 
spi ll s  on the 
operator’s glove,  
any surfaces  tou ch ed  
by th e opera tor  wi ll  
be con taminated .  
Liqu id spi lt  when 
removing swa b. 
Liqu id spi lt  when 
ti lt ing th e buf fer 
contain er  
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swab)  
 
Table 3 – Dry-run with GloGerm dye adopting the amended SOP 
 Care home A 
 
Care home B 





Description PPE correc tly d isposed 
af ter use in  a sealed bag 
Vial h older wi th n o 
sp ecimen sta ins  
Sample collection k it  set  up rea dy 
for swa bbing 
 
Usability 
Interview findings focussed on three main areas: 
1) Rapid test turnaround versus test throughput 
Fast test turnaround (~12 minutes) was valued. This was countered by an inability for staff members 
to handle more than one specimen at a time, and to carry on with their duties, especially if a large 
number of tests have to be conducted: “The senior members of staff, the nursing staff, they are not 
going to be committed that level of time […] you've got to go back every 12 minutes. So, it's taken up 
more of your time”. (CH3) 
Respondents identified specific use cases where LumiraDx was intuitively appealing: notably, 
sporadic testing such as testing of visitors at entrance to the home.  Small changes to workflow were 
seen as potentially enabling the integration of LumiraDx into home routines, for example by staff 
testing themselves one at a time after arrival at work.  
2) Biosafety issues and appropriate staff user profile 
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Spillage was the main biosafety characteristic identifed.  Participants recognised the mediating effects 
of safeguard measures and amended SOPs, but several staff felt testing was best undertaken by the 
more senior, and responsible, staff. Seniority was considered to be a function of time working in the 
home and/or could be denoted by a supervisor role.  “I don't trust them as much [junior staff 
members], you know, to clean up after themselves…to use an expensive piece of equipment to not 
abuse that, to make sure that they're writing the documentation down afterwards. So, for me, I would 
only be comfortable with somebody as a deputy manager or a manager level using the machine”. 
(CH2) 
LumiraDx is marketed as a bedside test for healthcare settings, but staff felt this to be inappropriate 
for a care home setting. This is because of the risk of spillage in areas with carpets and soft furnishing 
such as resident bedrooms. Further, it was seen as not appropriate in the communal parts of the home 
because the machine would be likely to attract attention from residents with cognitive impairment. 
Also, the machine made a noise during testing and the staff felt that residents would find this 
distressing, further limiting the proposed bedside use. 
3) Training materials 
Respondents generally found training materials easy to follow but several reported that appropriate 
personal protective equipment (PPE), including visors, needed emphasising.  Easily interpretable 
visual guides and a quick ‘prompt list’ mounted close to the machine would support operators 
recalling the operational steps, especially when use was infrequent (CH1).   
 
Testing agreement with laboratory RT-PCR 
In total 241 tests were run. Tests were carried out on 227 asymptomatic participants (159 staff and 68 
residents) and 14 symptomatic participants (5 staff and 9 residents) (Table 4; and Appendix IV, Table 
A2 stratified by staff/residents). Formal laboratory results were indeterminate for two specimens, both 
in asymptomatic participants, and so agreement analysis was conducted for 225 and 14 specimens. A 
Standard for Reporting of Diagnostic Accuracy Studies (STARD) Flow diagram is shown in Fig 3. 
The negative predictive value was 99.5% and 88.9% in asymptomatic and symptomatic participants, 
whilst positive predictive value was 10% and 100% in asymptomatic and symptomatic participants 
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respectively. A Standard for Reporting of Diagnostic Accuracy Studies (STARD) Flow diagram is 
shown in Fig 3. 
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Table 2 Full results from LumiraDx and Laboratory PCR 
Asymptomatic cases 
 Laboratory (qRT-PCR)  
LumiraDx Negative Positive Uncertain/error Total 
Positive 9 1 0 10 
Negative 214 1 2 217 
Uncertain/error 0 0 0 0 
Total 223 2 2 227 
Symptomatic cases 
 Laboratory (qRT-PCR)  
LumiraDx Negative Positive Uncertain/error Total 
Positive 0 5 0 5 
Negative 8 1 0 9 
Uncertain/error 0 0 0 0 
Total 8 6 0 14 
 
Table 3 - Agreement based on valid measures 
Asymptomatic cases 
 Laboratory (qRT-PCR)  
 negative  positive Total 
LumiraDx positive 9 1 10 
LumiraDx negative 214 1 215 
Total 223 2 225 
Test attributes  (95% CIs) 
Prevalence (LAB measure) 0.9% (0.1%  to 3.2%) 
Positive agreement (LAB positive as denom) 50% (1.3% to 98.7%) 
Negative agreement (LAB negative as denom) 96% (92.5% to 98.1%) 
Kappa 0.154 (-0.127 to 0.435) 
Prevalence and bias-adjusted Kappa (PABAK) 0.911 (0.857 to 0.965) 
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 Laboratory (qRT-PCR)  
negative positive Total 
LumiraDx positive  0 5 5 
LumiraDx negative 8 1 9 
Total 8 6 14 
Test attributes  (95% CIs) 
Prevalence (LAB measure) 42.9% (18% to 71.1%) 
Positive agreement (LAB positive as denom) 83.3% (35.9% to 99.6%) 
Negative agreement (LAB negative as denom) 100% (63.1% to 100%) 
Kappa 0.851 (0.573 to 1) 
PABAK 0.857 (0.549 to 1) 
 
Discussion 
Our three main findings were that: i) usability observations are required to adjust SOPs for testing to 
take account of specific biosafety challenges arising from the care home context; ii) use (and thus 
usefulness) is potentially limited if not integrated into workflow; and iii) training materials need 
specific adaptations to match the information-literacy of care home staff.   
As with other technologies we have evaluated in care homes [13], the utility of the LumiraDx test will 
depend on other factors including the care home built environment, staff competencies and workflow.  
The addition of LumiraDx to the range of tests that could be deployed in care homes, and the specific 
identification of a use case (e.g. testing of staff and visitors before entering the home), opens up a 
wider debate about what care homes require as we move into the next stage of the pandemic and 
beyond.  Staff highlighted the potentially restrictive impact of using LumiraDx on workflow because 
of the existing workload of staff members. We also identified issues regarding how testing may 
influence other aspects of care delivery. Staffing ratios in care homes mean that staff sometimes 
struggle to meet routine care requirements even under normal circumstances [22].  The introduction of 
time-consuming, and at present statutorily mandated, POCTs risks distracting staff from routine 
caring tasks. This may compromise the ethos of care in within homes.   The care sector should now 
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consider whether these technologies might be purchased and retained in the sector, and how to plan 
staffing for their deployment without incurring excessive opportunity costs. 
 
This was not a powered diagnostic accuracy study and the resulting negative and positive predictive 
values are a consequence of the low prevalence of positives in the group [23].  The good negative 
agreement suggests that LumiraDx may have some utility as a rule-out test. This could mean that it 
would work well in the context of a threshold test, which is the deployment suggested by care home 
staff.  This would need to be further validated in a cohort study to estimate the test’s negative 
predictive value in this population. In this context, the false positive rate would mean the need for 
formal confirmation through formal RT-PCR testing for those who test positive.  
 
The strengths of this study are that it provides a unique insight into the deployment of a novel POCT 
in care homes, a setting in which it has not previously been evaluated.  The careful consideration of 
biosafety issues using GloGermTM is, as far as we are aware, a first in this setting and could be 
replicated in future biosafety assessments in care homes.  The in-context data on what is required if 
the technology is to be successfully adopted for care home deployment, could only have been 
acquired using the methodologies deployed.  Study limitations include the small sample size. As such, 
the findings may not be representative of the 14,000 care homes across the UK. Further, it is 
recognised that the organisational factors identified in this sample of UK care homes may not be 
replicated internationally. Furthermore, we have limited knowledge of the physical properties of 
GloGermTM (e.g. viscosity) as an appropriate surrogate for a human specimen.  Nevertheless, the 
cautionary nature of our findings, about the need to evaluate new technologies in context in care 
homes, is likely to have wide application. 
 
Conclusions  
LumiraDx was successfully and safely deployed in care homes following adaption of the standard 
operating procedure. This took account of the care home environment and staff training.  LumiraDx 
increases the options for testing technologies that are available to care homes.  Future candidate 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted April 25, 2021. ; https://doi.org/10.1101/2021.04.22.21255948doi: medRxiv preprint 
 
technologies for roll-out in this sector should be subject to similar rigorous mixed-methods 
evaluation. A consideration of the health economic impact and opportunity costs associated with roll-
out of POCT in care homes is required. 
 
Funding statement 
This work was supported by National Institute for Health Research (NIHR), Asthma UK and the 
British Lung Foundation, as a part of the CONDOR study. MM, PB and PK are supported by the 
NIHR London In Vitro Diagnostics Co-operative; ALG is funded in part by the NIHR Applied 
Research Collaboration-East Midlands (ARC-EM). GH is supported by the NIHR Community 
Healthcare MedTech and IVD Cooperative. AJA is supported by the NIHR Newcastle In Vitro 
Diagnostics Co-operative. KD is seconded part-time into the technologies Validation Group, within 
Test and Trace. CT and KS are funded in part by the NIHR Applied Research Collaboration 
Yorkshire and Humber. DL is funded in part by the NIHR Applied Research Collaboration (ARC) 
West Midlands and the NIHR Community Healthcare MedTech and IVD Cooperative (MIC) at 
Oxford Health NHS Foundation Trust. RP acknowledges part-funding from the National Institute for 
Health Research (NIHR Programme Grant for Applied Research), the NIHR Oxford Biomedical 
Research Centre, the NIHR Oxford and Thames Valley Applied Research Collaborative (ARC), 
NIHR Oxford Medtech and In-Vitro Diagnostics Co-operative and the Oxford Martin School.  
The views expressed are those of the authors and not necessarily those of the funders, the NHS, the 
NIHR or the Department of Health and Social Care. LumiraDx were loaned, at no cost, by the 
supplier, LumiraDx UK Ltd.  The research team were independent of the manufacturer throughout 
and LumiraDx have not participated in the research and data analysis. 
 
Ethics 
This project was approved as a service evaluation by Imperial College Healthcare NHS trust (ICHNT) 
– registration no. 471. The collation of data from routinely collected specimens taken as part of 
mandated patient care was determined using the Health Research Authority online toolkit to be a 
service evaluation. 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)




The authors would like to thank care home managers and staff members who took part in the study 
and members of the CONDOR platform for their comments: Mr Graham Prestwich, Ms Vale Tate, 
and Dr David Ashley Price.  
 
References 
1. British Geriatrics Society. COVID-19: Managing the COVID-19 pandemic in care 
homes for older people. 2020.  (12/10/2020, date last accessed) 
2. Coronavirus (COVID-19): adult social care guidance. 
https://www.gov.uk/government/collections/coronavirus-covid-19-social-care-guidance 
(18 March 2021, date last accessed) 
3. Dagan N, Barda N, Kepten E, et al.; BNT162b2 mRNA Covid-19 vaccine in a 
nationwide mass vaccination setting. New England Journal of Medicine 2021. 
4. Cox LS, Bellantuono I, Lord JM, et al.; Tackling Immunosenescence to improve 
COVID-19 outcomes and vaccine response in older adults. The Lancet Healthy Longevity 
2020;1(2):e55-e57. 
5. Fontanet A, Autran B, Lina B, et al.; SARS-CoV-2 variants and ending the COVID-
19 pandemic. The Lancet 2021. 
6. Low L-F, Hinsliff-Smith K, Sinha S, et al.; Safe visiting at care homes during 
COVID-19: A review of international guidelines and emerging practices during the 
COVID-19 pandemic. 
7. Low L-F, Hinsliff-Smith K, Sinha SK, et al.; Safe visiting is essential for nursing 
home residents during the COVID-19 pandemic: an international perspective. Journal of 
the American Medical Directors Association 2021. 
8. Massimo Micocci, Adam L Gordon, A. Joy Allen, Timothy Hicks, Patrick 
Kierkegaard, Anna Mclister, Simon Walne, Gail Hayward, Peter Buckle, on Behalf of the 
Condor Study Team; COVID-19 testing in English care homes and implications for staff 
and residents. Age and Ageing 2021:1-5. 
9. Deeks JJ, Raffle AE; Lateral flow tests cannot rule out SARS-CoV-2 infection. 
British Medical Journal Publishing Group, 2020. 
10. Torjesen I; Covid-19: How the UK is using lateral flow tests in the pandemic. bmj 
2021;372. 
11. Preliminary report from the Joint PHE Porton Down & University of Oxford SARS-
CoV-2 test development and validation cell: 
Rapid evaluation of Lateral Flow Viral Antigen detection devices (LFDs) for mass 
community testing. 
https://www.ox.ac.uk/sites/files/oxford/media_wysiwyg/UK%20evaluation_PHE%20Port
on%20Down%20%20University%20of%20Oxford_final.pdf (14 December 2020, date 
last accessed) 
12. Innova Lateral Flow SARS-CoV-2 Antigen test accuracy in Liverpool Pilot: 
preliminary data, 26 November 2020. 
https://www.gov.uk/government/publications/innova-lateral-flow-sars-cov-2-antigen-
test-accuracy-in-liverpool-pilot-preliminary-data-26-november-2020 (16 December 
2020, date last accessed) 
13. Micocci M, Gordon A, Seo MK, et al.; Is Point-of-Care testing feasible and safe in 
care homes in England? An exploratory usability and accuracy evaluation of Point-of-
Care Polymerase Chain Reaction test for SARS-COV-2. medRxiv 2020. 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted April 25, 2021. ; https://doi.org/10.1101/2021.04.22.21255948doi: medRxiv preprint 
 
14. O’cathain A, Murphy E, Nicholl J; Three techniques for integrating data in mixed 
methods studies. Bmj 2010;341. 
15. Spilsbury K, Devi R, Griffiths A, et al.; SEeking AnsweRs for Care Homes during 
the COVID-19 pandemic (COVID SEARCH). Age and Ageing 2020. 
16. Ritchie J, Lewis J, Nicholls CM, et al. Qualitative research practice: A guide for 
social science students and researchers: sage, 2013. 
17. Braun V, Clarke V; Using thematic analysis in psychology. Qualitative research in 
psychology 2006;3(2):77-101. 
18. Department of Health and Social Care. Vivaldi 1: Coronavirus (COVID-19) care 
homes study report. https://www.gov.uk/government/statistics/vivaldi-1-coronavirus-
covid-19-care-homes-study-report (12 October 2020, date last accessed) 
19. Tulloch J, Micocci M, Buckle P, et al.; Enhanced Lateral Flow Testing Strategies in 
Care Homes Are Associated with Poor Adherence and Were Insufficient to Prevent 
COVID-19 Outbreaks: Results from a Mixed Methods Implementation Study. Available at 
SSRN 3822257 2021. 
20. UK Department of Health and Social Care. Technical Validation for LumiraDx 
SARS-CoV-2 Ag test. 
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachme
nt_data/file/970905/TVG_Report_LumiraDx-v2.pdf (16th March 2021, date last 
accessed) 
21. FDA, Statistical Guidance on Reporting Results from Studies Evaluating Diagnostic 
Tests - Guidance for Industry and FDA Staff. https://www.fda.gov/regulatory-
information/search-fda-guidance-documents/statistical-guidance-reporting-results-
studies-evaluating-diagnostic-tests-guidance-industry-and-fda (3 February 2021, date 
last accessed) 
22. Spilsbury K, Hewitt C, Stirk L, et al.; The relationship between nurse staffing and 
quality of care in nursing homes: a systematic review. International journal of nursing 
studies 2011;48(6):732-750. 
23. Altman DG, Bland JM; Statistics Notes: Diagnostic tests 2: predictive values. Bmj 
1994;309(6947):102. 
 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted April 25, 2021. ; https://doi.org/10.1101/2021.04.22.21255948doi: medRxiv preprint 
